WntRx Pharmaceuticals develops non-toxic selective drugs for the treatment of patients with colorectal cancer and critical unmet medical needs. It specializes in the development of oncogenic-specific inhibitors of Wnt signaling, a pathway aberrantly activated in a multitude of cancers. The company was founded in 2013 and is headquartered inBoston, Massachusetts.

Biotechnology

Health Care

Pharmaceutical

WntRx Pharmaceuticals

Jin Wang

Eric Cheng

Yanjun Ma

John Tagliamonte

David Zhu

Advisory Team

Leadership Team

Teams at WntRx Pharmaceuticals

Advisory Team

Leadership Team